Geode Capital Management LLC Has $5.88 Million Stake in Q32 Bio Inc. (NASDAQ:QTTB)

Geode Capital Management LLC increased its holdings in shares of Q32 Bio Inc. (NASDAQ:QTTB) by 22.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 131,768 shares of the company’s stock after acquiring an additional 24,114 shares during the quarter. Geode Capital Management LLC’s holdings in Q32 Bio were worth $5,881,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Values First Advisors Inc. acquired a new stake in Q32 Bio during the third quarter worth approximately $33,000. BNP Paribas Financial Markets increased its stake in shares of Q32 Bio by 199.1% during the third quarter. BNP Paribas Financial Markets now owns 1,298 shares of the company’s stock worth $58,000 after purchasing an additional 864 shares during the period. MetLife Investment Management LLC acquired a new stake in Q32 Bio during the 3rd quarter worth approximately $159,000. Barclays PLC boosted its stake in Q32 Bio by 105.2% in the 3rd quarter. Barclays PLC now owns 10,443 shares of the company’s stock valued at $465,000 after purchasing an additional 5,353 shares during the period. Finally, Rhumbline Advisers grew its holdings in Q32 Bio by 11,681.5% in the 2nd quarter. Rhumbline Advisers now owns 7,658 shares of the company’s stock valued at $137,000 after buying an additional 7,593 shares in the last quarter. Institutional investors own 31.32% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on QTTB. Guggenheim cut shares of Q32 Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 11th. Oppenheimer decreased their target price on shares of Q32 Bio from $80.00 to $20.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $16.00 price target (down from $95.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Leerink Partners reissued a “market perform” rating and set a $9.00 price target (down previously from $68.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Finally, BMO Capital Markets dropped their price objective on Q32 Bio from $64.00 to $22.00 and set an “outperform” rating for the company in a report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $29.86.

Q32 Bio Trading Up 13.3 %

Shares of QTTB stock opened at $3.91 on Friday. Q32 Bio Inc. has a fifty-two week low of $3.02 and a fifty-two week high of $53.79. The stock’s fifty day moving average price is $23.51 and its two-hundred day moving average price is $32.09. The company has a debt-to-equity ratio of 0.61, a quick ratio of 6.53 and a current ratio of 6.53. The company has a market cap of $47.63 million, a PE ratio of -0.27 and a beta of -0.46.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.